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Abstract
Reirradiation is a feasible option for patients who do not otherwise have treatment options available. Depending
on the location and extent of the tumor, reirradiation may be accomplished with external beam radiotherapy,
brachytherapy, radiosurgery, or intensity modulated radiation therapy (IMRT). Although there has been limited
experience with hypofractionated stereotactic radiotherapy (hSRT), it may have the potential for curative or
palliative treatment due to its advanced precision technology, particularly for limited small lesion. On the other
hand, severe late adverse reactions are anticipated with reirradiation than with initial radiation therapy. The risk of
severe late complications has been reported to be 20- 40% and is related to prior radiotherapy dose, primary site,
retreatment radiotherapy dose, treatment volume, and technique. Early researchers have observed lethal bleeding
in such patients up to a rate of 14%. Recently, similar rate of 10-15% was observed for fatal bleeding with use of
modern hSRT like in case of carotid blowout syndrome. To determine the feasibility and efficacy of reirradiation
using modern technology, we reviewed the pertinent literature. The potentially lethal side effects should be kept in
mind when reirradiation by hSRT is considered for treatment, and efforts should be made to minimize the risk in
any future investigations.
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Introduction
Locoregional failure is the predominant pattern of treat-
ment failure and the most common cause of death in
head and neck cancer patients [1]. As most recurrences
occur in the first 2 years after primary treatment and
80% arise in previously high-dose irradiated volumes,
reirradiation is a clinical challenge [2]. Chronic exposure
of the upper aerodigestive tract to alcohol and tobacco,
is the most common risk factor for head and neck can-
cer and is thought to produce field cancerization, a pro-
cess in which patients are at risk for developing cancer
at different mucosal sites. Second primary tumors in the
head and neck can occur in up to 30% of patients within
10 years of onset [3-5]. The preference in operable
patients is salvage surgery, with 5-year survival rates
ranging from 16-36% [3,6,7]. However, due to tumor
location and extent, medical contraindications, or
patient refusal, surgery is often limited and compro-
mised with close or positive margins, and only 20% of
patients would undergo salvage surgery [3,7]. The major
treatment has been palliative chemotherapy, which is
associated with a median survival time (MST) of 5-9
months and response rates between 10-40% [3,8,9]. A
few months of MST is generally anticipated for best
supportive care [10]. High-dose reirradiation in inoper-
able patients is the only treatment option with any
potential for cure. Reirradiation can be delivered using
brachytherapy, stereotactic radiosurgery, or external
beam radiotherapy with or without chemotherapy and
with or without prior debulking surgery. Evidently, bra-
chytherapy and stereotactic radiosurgery are attractive
options for small-volume disease [11]. Several centers
have reported encouraging results following aggressive
reirradiation with or without chemotherapy. In contrast,
reirradiation has caused severe adverse reactions in
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lethal bleeding rate in our retrospective analysis of
CyberKnife hSRT [12], in accordance with a recent
report that cited 15% incidence of lethal bleeding after
hSRT for carotid rupture syndrome [13]. Therefore, the
aim of this article is to identify the possible prognostic
and risk factors (particularly bleeding) for reirradiation,
including stereotactic irradiation.
Conventional radiotherapy (Table 1: additional file 1)
The earliest clinical studies of reirradiation were pub-
lished in the 1980s and most were based on single insti-
tution experiences dating back to 1950 [14,15]. Repeat
courses of radiation at 60 Gy, with total doses exceeding
120 Gy, were associated with severe complications;
deaths as a result of bleeding were already observed in 5
(2 with necrosis) of 35 patients (14%) in one study and
2 of 85 patients with recurrent tumors (2.3%) in another
study [14,15]. However, favorable clinical responses,
including significant rates of sustained local disease con-
trol (25-60%), were observed [9].
Ohizumi et al. treated 44 patients of recurrent squa-
mous cell carcinoma with cumulative dosing of more
than 80 Gy [16]. The complete response rate was 32%.
The median relapse-free survival time was 4 months,
and the 5-year survival was 6%. They found that the
anatomical location and an overlapping field of < 40
cm
2 were significant prognostic factors for survival.
Favorable sites were the nasopharynx, larynx, and oro-
pharynx; whereas, unfavorable sites were the oral cavity,
nasal cavity, and hypopharynx. Severe late complications
occurred in 5 (11%) patients.
De Crevoisier et al. reported the results of 169
patients with unresectable nonmetastatic head and neck
cancers in a previously irradiated area [17]. Reirradiation
protocols were as follows: radiotherapy alone (65 Gy
over 6.5 weeks at 2 Gy/day) in 27 patients; Vokes proto-
col, i.e., 5-6 cycles of radiotherapy (median total dose,
60 Gy; 2 Gy/day) with simultaneous 5-fluorouracil (5-
FU) and hydroxyurea in 106 patients; and bifractionated
radiotherapy (median total dose, 60 Gy; 2 × 1.5 Gy/day)
with concomitant mitomycin, 5-FU, and cisplatin in 36
patients. The median cumulative dose of the 2 irradia-
tions was 120 Gy. Forty-four percent were local recur-
rences, 23% nodal recurrences, 14% both local and
nodal recurrences, and 19% were second primary
tumors. Mucositis grade 3 and 4 were observed in 32%
and 14% of cases, respectively. Late toxicities (> 6
months) were as follows: cervical fibrosis (grade 2 to 3),
11%; mucosal necrosis, 21%; osteoradionecrosis, 8%; and
trismus, 30%. Five patients died of carotid hemorrhage,
apparently in complete remission. Thirty-seven percent
of patients had complete responses. Patterns of failure
were local only (53%), nodal only (20%), metastatic only
(7%), and multiple (20%). The overall survival rate was
21% at 2 years and 9% at 5 years. The MST was 10
months for the entire population. Thirteen patients, of
whom 12 were treated with the Vokes protocol, were
long-term disease-free survivors. In a multivariate analy-
sis, the volume of the second irradiation was the only
factor significantly associated with the risk of death.
Salama et al. reviewed the University of Chicago
experience with reirradiation in 115 patients from sev-
eral chemoradiation trials [18]. Patients were treated
with multiple 2-week cycles of 5 days of chemora-
diotherapy, followed by a 9-day break. Radiotherapy was
administered either daily or twice daily (bid), with a
mean total dose of 64.8 Gy. The majority of patients
were treated with computed tomography (CT)-based
conformal radiotherapy. The MST was 11 months, and
the 3-year overall survival rate was 22%. Approximately
41% of patients developed locoregional disease recur-
rence. Increasing the reirradiation dose, surgery before
chemoradiation, and the use of cisplatin, paclitaxel, or
gemcitabine were found to be significant predictors of
improved survival. Toxicity was significant in 19 patients
(17%) who died of treatment-related toxicity and 57% of
patients who required a gastrostomy.
Spencer et al. reported results of the Radiation Ther-
apy Oncology Group (RTOG) reirradiation trial (RTOG
96-10) conducted between 1996 and 1999 that included
81 patients [19]. All patients had unresectable squamous
cell carcinomas and at least a 6-month interval between
prior radiation and reirradiation (61 recurrences and 18
second primaries). The patients received a split-course
regimen of radiation (total dose 60 Gy, 1.5 Gy fractions,
bid) with concurrent 5-FU and hydroxyurea. Grade 3 to
4 mucositis occurred in 17% of patients, and lethal side
effects occurred in 7.4% of patients (6/81). The 2-year
overall survival rate was 16% (MST: 8.8 months). Survi-
val among patients who had a longer interval between
primary radiation and reirradiation was longer compared
with those who had a shorter interval. Thereafter, Lan-
ger reported a succeeding RTOG 99-11 trial that
employed hyperfractionatedr a d i o t h e r a p y( 1 . 5G yb i d )
for 2 weeks × 4 times with 2-week intervals, concomi-
tant with daily cisplatin (15 mg/m
2) and paclitaxel (20
mg/m
2) during radiation, and granulocyte colony-stimu-
lating factor during the off weeks [10]. The patients in
that study had a 25.9% 2-year survival rate (MST: 12
months) and a mortality rate of 7.6% (8 patients). These
results were an improvement over those observed in
RTOG 96-10. Accordingly, to compare reirradiation and
concurrent chemotherapy with chemotherapy alone in
inoperable, previously irradiated, locally recurrent or
second primary cancer, study RTOG 0421 (n = 240) was
initiated. The concurrent reirradiation and chemother-
apy arm of this trial used the same regimen as in RTOG
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one of the 3 cisplatin-based chemotherapy regimens
(cisplatin + paclitaxel, docetaxel, or 5-FU). The primary
end point of this trial was survival. Unfortunately, this
study ended prematurely because of inadequate accrual
[20], presumably from a lack of provider interest in ran-
domizing patients away from radiation treatment. Gen-
erally, the Western trials employed hyperfractionation
radiotherapy on the basis of the assumption that lower
single fractionation levels may reduce late adverse reac-
tions. In addition, treatment strategies have used con-
current chemotherapy to overcome the decrease of
radiation doses and possibly reduce metastatic failure.
Reentry McDonald et al. made a review that there were
41 reported Carotid blowout among 1554 patients receiv-
ing salvage reirradiation (2.6%); 76% were fatal [21]. In
patients treated in a continuous course with 1.8-2-Gy daily
fractions or 1.2-Gy twice daily fractions, 36% of whom
received concurrent chemotherapy, the rate of carotid
blowout was 1.3%, compared with 4.5% in patients treated
with 1.5 Gy twice daily in alternating weeks or with
delayed accelerated hyperfractionation, all of whom
received concurrent chemotherapy (p = 0.002). There was
no statistically significant difference in the rate of carotid
blowout between patients treated with or without concur-
rent chemotherapy, or between patients treated with or
without salvage surgery before reirradiation.
Brachytherapy
Brachytherapy has achieved good local control in
selected patients. Hepel reported of experiences in 30
patients reirradiated by high-dose-rate brachytherapy
[22]. All of these patients were either inoperable, refused
surgery, or had gross residual disease after salvage sur-
gery for their recurrent disease. Thirty-six sites in these
30 patients were implanted by application of high-dose-
rate interstitial brachytherapy technique with a tumor
dose of 34 Gy (18-48 Gy) delivered by application of
300-400 cGy fractions, bid. Local tumor control was
achieved in 69% of the implanted sites. Overall survival
at 1 and 2 years was 56% and 37%, respectively. Grade 3
and 4 late complications occurred in 16% of the
patients; however, no fatal complications were seen [22].
Although brachytherapy has a potential to cure oral,
oropharyngeal, nasopharyngeal, and lymph node recur-
rences [20], only superficial small tumors can be treated,
and the number of experienced institutions is limited.
Intensity-Modulated Radiotherapy (IMRT)
A newer advancement in radiotherapy technique that
facilitates precise dose delivery is the IMRT. This tech-
nique allows dose-escalation while minimizing normal
tissue toxicity. Early reports suggest that IMRT can be
used in an irradiation setting.
Sulman reported 58% 2-year survival rate and 64%
local control rate by reirradiation using IMRT. Twenty
percent of patients required admission and 1.4% suffered
treatment-related deaths [20]. Twenty (27%) patients
underwent salvage surgical resection and 36 (49%)
received chemotherapy. The median reirradiation dose
was 60 Gy and the median lifetime radiation dose was
116.1 Gy. Severe irradiation-related toxicity occurred in
15 patients (20%), and 1 treatment-related death was
observed.
Popovitzer et al. reported on the appropriateness of
limited-field irradiation for recurrent tumors. In an ana-
lysis of 66 cases of recurrence, only 2 recurred outside
the irradiated area (4%); whereas, 50 recurred within the
95% isodose lines of the irradiated field, although a dose
of 68 Gy was employed [23]. They concluded that a pro-
phylactic field is not needed in reirradiation at present.
The actuarial 2-year overall survival rate was 40%, and
71% of all patients developed a locoregional failure after
68 Gy of hyperfractionated radiotherapy. Mild to moder-
ate late complications were common; 29% of patients
experienced late morbidity of at least grade 3 or more.
Two patients died of therapy-related complications (one
cisplatin-induced renal failure, and one from aspiration).
Two patients developed carotid artery blowouts, which
were successfully salvaged.
Duprez et al. reported outcomes for 84 patients trea-
ted with IMRT (median dose, 69 Gy). Salvage surgery
preceded reirradiation in 19 patients and 17 patients
received concurrent chemotherapy [24]. Five-year locor-
egional control and overall survival were 40% and 20%,
respectively. Stage T4, the time interval between initial
treatment and reirradiation, and hypopharyngeal cancer
were independent prognostic factors that showed worse
overall survival from multivariate analysis. Twenty-six
and 11 patients developed Grade 3 acute and late toxi-
city, respectively. No Grade 5 acute toxicity was
observed. There were 2 fatal vascular ruptures during
follow-up.
Biagioli et al evaluated their experience using every
other- week IMRT with concurrent chemotherapy [25].
Patients who underwent surgery as a part of their sal-
vage therapy had a mean estimated survival of 30.9
months compared with 22.8 months for patients who
received only chemoradiotherapy (p = 0.126). Grade 3
or 4 acute toxicities occurred in 31.7% of patients, but
all had resolved within 2 months of therapy completion.
No deaths occurred during treatment, except for 1
patient, who died shortly after discontinuing treatment
early because of previously undiagnosed metastatic dis-
ease; 6 patients had long-term complications. They con-
cluded that concurrent chemotherapy with repeat
radiotherapy with IMRT given every other week appears
to be both well tolerated and feasible in patients treated
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cancer.
Lee et al. reported that patients who underwent
I M R T ,c o m p a r e dt ot h o s ew h od i dn o t ,h a dab e t t e r2 -
year LRPF (52% vs. 20%, p < 0.001) [26]. On multivari-
ate analysis, non-nasopharynx and non-IMRT were
associated with an increased risk of loco-regional (LR)
failure. Patients with LR progression-free disease had
b e t t e r2 - y e a ro v e r a l ls u r v i v al vs. those with LR failure
(56% vs. 21%, p < 0.001). Acute and late Grade 3-4 toxi-
cities were reported in 23% and 15% of patients. Severe
Grade 3-4 late complications were observed in 12
patients, with a median time to development of 6
months after re-RT. They concluded that the use of
IMRT predicted better LR tumor control
Stereotactic radiosurgery (SRS)/Stereotactic radiotherapy
(SRT) (Table 2: additional file 2)
With precise dose delivery, SRS/SRT has a physical
advantage that allows highly conformal dose distribution
and highly accurate dose-delivery to within a few mm
for extracranial head and neck lesions [27]. The practi-
cal advantage is in terms of the short duration of treat-
ment, generally lasting 1 day for SRS and approximately
2 weeks of alternate-day treatment for SRT. The lack of
hematological or systemic toxicity permits inclusion of
patients in poor general condition. Acute mucositis has
been temporary and is well managed with supportive
care. Siddiqui et al. treated 21 recurrent (n = 21) tumor
patients with SRS/SRT [27]. Radiation doses were either
single fractions of 13-18 Gy or 36-48 Gy in 5-8 frac-
tions. The tumor control rate at 1 year was 60.6% and
the MST was 6.7 months.
Treatment using the CyberKnife robotic system has
several merits compared with g-Knife treatment because
the CyberKnife system can give a homogeneous dose
distribution using fractionated image-guided radiother-
apy, resulting in noninvasive fixation even for other
than cranial lesions [28]. Roh et al. reported an 80%
response rate (complete + partial) by with 30 Gy (range:
18-40 Gy) in 3-5 fractions by SRT using the CyberKnife
system, which resulted in a 2-year survival rate of 30.9%.
Late adverse reactions occurred in 8.6% of patients
including 2.9% treatment-related deaths [29]. Other
researchers have also achieved high efficacy using
Cyberknife reirradiation, with response rates of over
70% and 2-year overall survival rates of 30% [28,30].
The University of Pittsburgh group initiated a phase I
dose-escalation clinical trial [31]. Twenty-five patients
were treated in 5 dose tiers with up to 44 Gy, adminis-
tered in 5 fractions over a 2-week course. Neither grade
3/4 nor dose-limiting toxicities occurred. Four patients
had Grade 1 or 2 acute toxicities. Four objective
responses were observed for a response rate of 17%.
Twelve patients had stable disease. The median time to
disease progression was 4 months, and the MST was 6
months. Self-reported quality of life was not significantly
affected by treatment. Fluorodeoxyglucose PET was a
more sensitive early measure of response to treatment
than CT volume changes. They concluded that reirra-
diation with up to 44 Gy using SBRT was well tolerated
with no grade 4 or 5 treatment-related toxicities in the
acute setting. Following this work, Rwigema et al.
reported SRT outcomes in 85 patients using the Cyber-
Knife system or Trilogy-IMRS that used a Varian stereo-
tactic treatment-planning system [32]. The mean total
dose of prior radiation to the primary site was 74 Gy
(range: 32-170 Gy). Patients who were treated with ≥ 35
Gy had a significantly higher local control rate com-
pared with those who received < 35 Gy (71% vs. 59%,
respectively). This difference in local control rates was
larger at tumor size greater than the median tumor
volume (i.e., > 25 mL, 62% vs. 47%) compared with
smaller volume disease (i.e., ≤ 25 mL, 80% vs. 71%).
There were 34% complete responses and 34% partial
responses; 20% of patients developed stable disease and
12% developed progressive disease. Among those with
an initial tumor response followed by progression (58
patients), there was a median interval of 5.5 months for
time to progression. The 1-year and 2-year local control
and overall survival rates for all patients were 51.2% and
30.7%, and 48.5% and 16.1%, respectively. Overall, the
MST for all patients was 11.5 months [32].
Georgetown university group reported feasibility of
SRS/SRT reirradiation [33]. From 2002 to 2008, 65
patients received SRS/SRT and thirty-eight patients were
treated definitively and 27 patients with metastatic dis-
ease and/or untreated local disease were treated pallia-
tively. Nine patients underwent complete macroscopic
resection before SRS/SRT. Thirty-three patients received
concurrent chemoradiation. The median reirradiation
SRS/SRT dose was 30 Gy (21-35 Gy) in 2-5 fractions.
Fifty-six patients were evaluable for response: 30 (54%)
had complete, 15 (27%) had partial, and 11 (20%) had
no response. MST was 12 months. For definitively trea-
ted patients, the 2-year overall survival and locoregional
control rates were 41% and 30%, respectively. Multivari-
ate analysis demonstrated that surgical resection and
nonsquamous histology were associated with improved
survival. Seven patients (11%) experienced severe reirra-
diation-related toxicity, including one treatment-attribu-
ted death.
Kodani et al. evaluated the efficacy and safety of
stereotactic body radiation therapy for patients with
head and neck tumors [12]. Twenty-one patients were
treated with CyberKnife SBRT. The prescribed dose ran-
ged from 19.5 to 42 Gy (median, 30 Gy) in 3-8 fractions
for consecutive days. The target volume ranged from 0.7
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tolerated without significant acute complications in any
cases. The overall survival rates was 50% at 24 months.
The overall survival was better in patients without prior
radiotherapy within the previous 24 months or in case
of smaller target volume. Six patients suffered severe
late complications, and 2 of them developed massive
hemorrhage in the pharynx and both died of this com-
plication 5 and 28 months, respectively..
Site-specific consideration: Nasopharyngeal cancer (Table
3: additional file 3)
A substantial amount of data on reirradiation has been
accumulated for nasopharyngeal carcinoma (NPC),
although high evidence level data is not available
[34-40]. Yu et al. reported on 275 patients from the
Hong Kong Nasopharyngeal Study Group database who
were evaluated for a first isolated local recurrence
between 1996 and 2000 [34]. Two hundred patients
received salvage treatment including external radiother-
apy, brachytherapy, and/or surgery. The 3-year actuarial
overall survival rate for patients with isolated local fail-
ure was 74%. On multivariate analysis, advanced initial
T classification and the use of salvage treatment were
independent prognostic factors. Symptomatic temporal
lobe necrosis occurred in approximately 12% of patients
and was the most morbid complication, with a mortality
rate of 65%. As surgery can treat only limited small
volume tumors, radiotherapy was used most often.
However, there is little evidence for selection among the
radiotherapeutic modalities. Treatment mode should be
selected according to each patient’s condition by deter-
mining age, performance status, tumor location, size,
histology, past treatment, and the will of the patient.
Law et al. cited effectiveness of intracavitary mold bra-
chytherapy in salvaging NPC with early-stage local per-
sistence or first recurrence [35]. The overall complete
remission rate was 97%. The rates of 5-year local con-
trol, relapse-free survival, disease-specific survival, over-
all survival, and major complication were 85%, 68.3%,
74.8%, 61.3%, and 46.9%, respectively. Major complica-
tions included nasopharyngeal necrosis with headache,
necrosis of cervical vertebrae with atlantoaxial instabil-
ity, temporal lobe necrosis, and palsy of the cranial
nerves. The afterloaded mold was as effective as the pre-
loaded version, but with fewer complications.
Wu et al. reported outcomes of SRT for 56 recurrent
cancers from Tat-Sen University in Gantong, China
[37]. They achieved a 3-year local progression-free survi-
val rate of 75% by 48 Gy delivered in 6 fractions of SRT.
Severe lethal adverse reactions were 2 bleeding episodes
and 3 brain stem necroses.
Seo et al. reported good outcomes (23 complete
responses, 5-year overall survival rate of 66%, local
failure-free survival rate of 79%) for 35 nasopharyngeal
cancer patients who received 33 (range: 24-45) Gy in 3-
5 fractions by SRT using CyberKnife [38]. Favorable
prognostic factors for overall survival were an early
stage rT (recurrent T category, rT1-2: 80% vs. rT3-4:
39%) and age. Five patients showed adverse reactions of
Grade 4-5.
Chua et al. designed a prognostic scoring system for
radiosurgery [39]. A total of 48 patients with local fail-
ures of NPC were treated by stereotactic radiosurgery.
The treatment was administered with a median dose of
12.5 Gy to the target periphery. The 5-year local failure-
free probability after radiosurgery was 47.2% and the 5-
year overall survival rate was 46.9%. Neuroendocrine
complications occurred in 27% of patients but there
were no treatment-related deaths. Five factors including
age > 45 (age), time interval from primary radiotherapy
> 6 months (time), rT4 disease (rT4), tumor volume
≥10 cc (tvol), and prior local failure (prior LF) were
used to design the scoring system; the prognostic score
= 0.22 × age (0, 1) + 0.27 × time interval > 6 months (0,
1) + 0.05 × rT4 (0, 1) + 0.28 ×Tvol (0, 1) + prior local
recurrence (0, 1). Patients were then grouped by the cal-
culated prognostic score: good prognostic group, 0 (i.e.,
those without any poor prognostic factors, n = 12),
intermediate prognostic group, > 0 to 0.5 (n = 23), and
poor prognostic group, > 0.5 (n = 13). The 5-year local
failure-free probabilities in patients with good, inter-
mediate, and poor prognostic scores were 100%, 42.5%,
and 9.6%, respectively. The corresponding 5-year overall
survival rates were 100%, 51.1%, and 0%, respectively.
Furthermore, Chua et al. also reported the superiority
of SRT over SRS in a case control study [40]. They com-
pared 43 cases of 12.5 Gy SRS and 43 cases of 34 Gy
delivered in 2-6 fractions of SRT. The 1- and 3-year
local failure-free survival rates were 70% and 51% for
the SRS group and 91% and 83% for the SRT group (P
= 0.003). Although the overall survival rates were similar
(66% in SRS and 61% in SRT), severe side effects
occurred at a rate of 33% for SRS (brain necrosis, 16%;
bleeding, 5%), and 21% for SRT (brain necrosis, 12%;
bleeding, 2%).
Other lesions
Oropharyngeal and oral cancer have been good candi-
dates for reirradiation treatments. For small recurrences
in the larynx after conventional radiotherapy, Wang et
al. reported excellent salvage outcomes by reirradiation
in recurrent laryngeal cancer [41]. Single or a few lymph
node recurrences also could be treated by reirradiation
including brachytherapy or SRT [26,30,42]. Oral cancer
can be salvaged by brachytherapy. However, upper gum,
retromolar trigone, and palatal lesions were at a risk of
fistula formation. Ogita et al. reported that prior surgical
Yamazaki et al. Radiation Oncology 2011, 6:98
http://www.ro-journal.com/content/6/1/98
Page 5 of 10intervention or subcutaneous wide-spread tumor invol-
vement were risk factors for post-radiotherapy refractory
ulceration and bleeding [30]. There is no consensus on
the usage of hSRT for larynx or hypopharynx, where
swallowing movement may influence outcomes, since
there is a general uncertainty in the homogeneity and
reproducibility of dose distribution.
Prognostic factors for survival outcome by reirradiation
(Table 4: additional file 4)
Debulking surgery
De Crevoisier et al. reported the long-term results of
salvage surgery prior to reirradiation in a small series of
25 patients [6]. In this series, patients who had positive
margins and/or lymph node involvement with extracap-
sular extension following attempted salvage surgery
were reirradiated with concomitant chemotherapy, con-
sisting of 5-FU (800 mg/m
2/day) and hydroxyurea (1.5
g/day). Radiation was delivered once daily for a total
dose of 60 Gy in 2 fractions. Treatment was delivered as
a 14-day cycle with 5 days of treatment followed by a 9-
day break. These authors reported a 4-year survival of
43% and a 5-year disease-free survival of 26%. Surgical
resection has the additional advantage of removing
radioresistant disease. To address this, the Groupe
d’E t u d ed e sT u m e u r sd el aT e t ee td uC o ua n dG r o u p e
d’Oncologie Radiotherapie Tete et Cou groups in France
jointly sponsored a phase III trial, which randomized
130 patients to surgery with or without adjuvant doses
of 60 Gy and concurrent 5-FU/hydroxyurea. Progres-
sion-free survival was significantly improved in the adju-
vant therapy arm, with an increase in acute and late
complications. However, no overall survival benefit has
been detected so far [43].
Tumor size rT1 to 3 vs. T4, T category/irradiated volume
Nonbulky tumors showed a trend toward improved
tumor control, and patients with a low volume of dis-
ease prior to reirradiation were most likely to benefit
from aggressive locoregional treatment [2,3,12,17,24,32,
34,35,37-39,44]. In the same manner, smaller irradiated
volume resulted in better outcomes, partly because a
higher dosage of radiotherapy could be administered
than that for a larger tumor [12,16].
Anatomical site
Among, highly selected patients, good outcomes were
seen in patients with nasopharyngeal or laryngeal cancer
in several studies [2,12,16,39-41], whereas hypopharyn-
geal cancer revealed poor prognosis [16].
Time interval since prior irradiation
Several studies including our own have reported the
time interval to failure as an important prognostic factor
[12,15,18,19,24,39]. Spencer et al. reported that the 1-
year survival rate for patients treated within 3 years of
prior radiotherapy was 35% compared with 48% for
patients treated for > 3 years from prior radiotherapy,
based on data from 81 patients (RTOG 96-10). Other
patients who received their initial course of radiotherapy
24 months or more before the repeat course had a MST
of 15 months vs. 6.5 months in patients who were trea-
ted within 1 year of their therapy [19].
Second primary versus recurrent tumor
As time to recurrence increases, it is more difficult to
distinguish between a late recurrence and a second pri-
mary cancer; therefore, second primary have shown bet-
ter outcomes than recurrence. New primary cancers
should respond better to treatment than recurrent
tumors in a previously irradiated field due to the inher-
ent aggressiveness and radioresistance of recurrent
tumor cells. Several studies have reported data, which
support this hypothesis [11]. Based on data from the 81
patients treated in the RTOG 96-10 study, Spencer et al.
reported that the 1-year survival rate and MST for
patients with a second primary were 54% and 19.8
months, respectively compared with 38% and 7.7
months, respectively for patients with recurrent cancers
[19]. Stevens et al. analyzed 100 patients treated with
reirradiation alone and reported a 5-year actuarial over-
all survival and locoregional control of 17% and 27%,
respectively for recurrent tumors compared with 37%
and 60%, respectively for second primary cancers in a
previously irradiated field [15].
Dose-response
Several reports have cited dose as a prognostic factor in
reirradiated tumors [26,33]. The requirement of high-
dose irradiation is because radiation-resistant clonogens
could be a source of recurrence. In general, it is hard to
imagine that smaller doses than used in the original
irradiation treatment will be curative. Actually, despite
aggressive therapy with high doses of reirradiation con-
comitant with chemotherapy, the majority of failures are
still locoregional, illustrating the high proportion of
radioresistant cells in recurrent tumors [23]. The Uni-
versity of Chicago found that the median and 2-year
survival for patients receiving 58 Gy or more were 11.3
months and 35%, respectively compared with 6.5
months and 8%, respectively for patients receiving a les-
ser dose [18]. Also in an SRT series, a prescribed dose
of 35 Gy or more and tumor volume of 25 mL or less
had a better local control rate [32].
Risk factors for adverse events (Table 4: additional file 4)
I tc a ng e n e r a l l yb es t a t e dt h a tt h ei n c i d e n c eo fh i g h -
grade toxicity associated with reirradiation is substantial.
T h er i s ko fs e v e r el a t ec o m p l i c a t i o n sw a sr e p o r t e da s
20-40% and was related to prior radiotherapy dose, pri-
mary site, retreatment radiotherapy dose, treatment
volume, and technique. Although the reported frequency
of high-grade acute toxicities varies greatly from study
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and dermatitis have been universally reported to occur
in majority of patients. The incidence of grade 3 to 4
mucositis, including dysphasia requiring a feeding tube
or gastrostomy, has been generally reported to occur in
10- 40% of patients [19]. Grade 3 dermatitis has been
observed in < 10% of patients. The frequency of signifi-
cant hematological toxicity varies considerably in the lit-
erature and appears to depend largely on the
chemotherapy regimen used. Ulcer formation has been
frequently found in cases with histories of previous sur-
gical intervention or mucosal involvement. Ogita et al.
reported that ulcer formation occurred in 53.2% of cases
with mucosal involvement vs. 30.7% without mucosal
involvement using CyberKnife SRT at 1 year after treat-
ment [30]. Other chronic adverse reactions that
occurred were as follows: cranial nerve palsies, brain
necrosis (temporal lobe, etc.), osteoradionecrosis (skull
base, mandibular, etc.), palatal fibrosis, trismus, aspira-
tion, hormonal dysfunction, headache, otitis media and
hearing impairment, corneal ulcer, retinopathy, cere-
brospinal fluid leakage, brain herniation, and radiation
induced malignancy.
Life-threatening toxicities caused by reirradiation
occur infrequently; however, by nature they are quite
worrisome. Carotid rupture in the setting of reirradia-
tion in nearly all instances results in death [12,13]. De
Crevoisier et al. reported 5 such cases, the University of
Chicago reported 6 cases (1 where the patient survived),
and 2 cases were reported in RTOG 99-11 [10]. Gener-
ally, those treated by conventionally fractionated reirra-
diation reported bleeding rates of 3-14%, and a recent
IMRT series reported bleeding rates of 0-3%
[4,14,21,24]. On the other hand, several SRS and hSRT
series have reported higher rates (9-15%) of bleeding,
including CyberKnife hSRT [12,13,36]. Cengiz et al.
reported a high incidence (15%) of bleeding after SRT
by the Cyberknife system [13], which is similar to our
experiences of bleeding rates (9.5%). These studies
reported that this fatal syndrome occurred only in
patients with tumors surrounding carotid arteries and
where the carotid arteries received all of the prescribed
dose. Necrosis frequently appears before bleeding, and it
has been difficult to make a differential diagnosis of
recurrence with or without infection [12,13,36]. Xiao et
al. described several considerations regarding bleeding
after reirradiation for NPC based on their experience
with 8 cases of bleeding. For a tumor involving the
Rosenmueller fossa that invades deeply into the foramen
lacerum, which is the location where the cervical por-
tion of the internal carotid artery curves upward and
enters the cranium is problematic as it is very near the
Rosenmueller fossa [36]. This anatomical site is quite
vulnerable to hemorrhage, particularly, when the tumor
has not only surrounded the arterial wall but has also
invaded and damaged it. Furthermore, when the artery
has been weakened and affected by infection and necro-
sis, copious bleeding easily occurs. Bleeding may also be
caused by due to the following: a total high local dose
resulting from a second course of external irradiation,
complicating diabetes mellitus, and a single dose that is
too high (1 patient received 15 Gy in one fraction plus
12 Gy in another fraction over 12 days). After this
patient’s death, the single dose was reduced for subse-
quent patients.
Discussion
Outcomes after reirradiation of tumors are variable, and
5-year survival rates range from as low as 3.8% in unse-
lected patients to as high as 100% in selected patients
[19,39]. We could not find any randomized prospective
trial to determine the best radiotherapy schedule and
modality. The interpretation of the small number of
prospective and the many retrospective studies including
inhomogeneous patient characteristics was inconclusive.
Several complicating factors included variety of patients
with recurrent and second primary tumors, limited and
advanced tumors, curative and palliative treatment,
squamous cell carcinoma and other histologies, and
variable treatment strategies. Several studies have
demonstrated that reirradiation is a feasible option in
previously irradiated head and neck cancer patients. As
noted above, the treatment options for these patients
are limited. Several studies have used different inclusion
criteria for reirradiation. The RTOG trials were some-
what more stringent than other series and in that at
least 75% of the irradiated tumor volume had to be pre-
viously treated with at least 45 Gy. Other studies classi-
fied patients with any overlap between initial and
salvage treatment as having been reirradiated [16,20]. As
discussed, patients with resectable disease frequently
enjoy improved salvage rates. Such patients are fre-
quently offered adjuvant reirradiation alone or with che-
motherapy. The likelihood of cure is impacted by the
interval between the initial course of radiotherapy and
reirradiation depending on, whether the carcinoma is a
recurrence or a second primary tumor, initial T-stage
(rT stage), whether the tumor is isolated or local-regio-
nal, and the histology (Table 4: additional file 4) [11].
A practical advantage of hSRT is the shorter duration
of treatment, with SRS generally lasting 1 day and alter-
nate-day hSRT lasting approximately for 1 to 2 weeks.
Also, the lack of hematological or systemic toxicity per-
mits the inclusion of patients in poor general condition.
Acute mucositis has been temporary and well managed
with supportive care. The physical advantage of stereo-
tactic radiation arises from the ability to achieve a highly
conformal dose distribution and deliver the treatment
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ered in such advanced limited field radiotherapy. Con-
tour delineation is a problem to be resolved, especially
in multi-institution trials. There is a wide range of
deviation in GTV, CTV, and PTV delineation methods
and the prescribed methods are varied (D50 to D95),
depending largely on the physician’s decision, all of
which become more important if employed for a limited
small field [45].
T h eb i o l o g i c a le f f e c t i v ed o s e( B E D )f o r m u l ah a sn o t
been established for treatment effectiveness of hSRT
because of the lack of experimental validity when large
doses per fraction and short overall treatment times have
been used. However, the BED formula currently serves as
a useful model for biological comparison of different
fractionations, particularly for adverse reactions. For esti-
mation of late complications, King et al. made a consid-
eration for rectal mucosal side effects in prostate cancer
radiotherapy. They gave 5 × 7.25 Gy = 36.25 Gy for pros-
tate stereotactic body radiotherapy and reported that a
reduced rate of severe rectal toxicity was observed with
treatment every other day vs. treatment over 5 consecu-
tive days (0% vs. 38%, P = 0.0035), although none was as
high as Grade 3. They predicted that the acute equivalent
total dose in 2-Gy fractions was 52.1 Gy for treatment
with “daily” fractions (5 fractions per week) but only 50.8
Gy for treatment every other day [46]. In addition, the
University of Pittsburgh group was able to escalate the
dose up to 44 Gy in 5 fractions without any carotid blow
out syndrome using daily protocol, even though follow-
up periods were short [31]. They used every-other-day
(QOD) hSRT which may contain the potential impact on
adverse toxicities because most of the papers in hSRT
that have seen high incidences of carotid blow-out for
example used a once-daily (QD) hSRT approach.
IMRT can optimize the treatment plan and more
easily spare critical structures thus reducing adverse
reactions. These benefits have been proven in various
fields and may also apply to reirradiation patients.
Therefore, higher risk patients, such as those in whom
the tumor involves more than half the circumference of
the carotid artery, might be better candidates for treat-
ment by IMRT with conventional fractionation. In con-
trast, some investigators argue that the dose
inhomogeneity and inaccurate delivery to tumor lesions
noted in inverse planning can lead to inadequate target
coverage. To overcome the problems of precise location
and changing shape of the tumor during treatment peri-
ods, image-guided radiotherapy and adaptive radiother-
apy were introduced in several institutions. In addition,
we anticipate that the ability of IMRT to carefully sculpt
the dose around critical structures and thus increase the
total dose, will outweigh the theoretical concerns of an
increased volume of tissue receiving low-dose radiation.
However, the availability of IMRT is limited, and some
patients cannot endure long radiotherapy schedules of
5-6 weeks or more. For patient convenience, hSRT
should be explored further.
One of the future trends is development of drugs such
as EGFR inhibitors that have improved outcomes in head
and neck cancer treatment [47]. A recent European ran-
domized trial showed that addition of cetuximab, the first
clinically available EGFR-directed monoclonal antibody,
to a standard chemotherapy regimen (platinum/5-FU)
led to an improved survival benefit. This study, with sup-
port from the results of an additional smaller study in the
US, has changed practice [47]. Accordingly, additional
EGFR blockade trials in reirradiation are ongoing in sev-
eral institutions [48,49]. Heron et al reported the result
of phase II study (a single institution matched case-con-
trol study) that cetuximab conferred an overall survival
advantage (24.5 vs. 14.8 months) when compared with
the stereotactic body radiotherapy alone arm, without a
significant increase in grade 3/4 toxicities [49].
In conclusion, reirradiation treatment is a challenging
field but is feasible and potentially beneficial for patients
who otherwise may not be salvaged by other available
options. Future investigation is warranted but should
include careful patient selection with consideration of
the radiotherapy schedule, tumor factors as well as
patient history and characteristics.
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